| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02668822 2015-004326-34 Details | 2022-02-04 Interventional | 3 | 18 | Ibuprofen Dysmenorrhea | Study terminated by Sponsor as a result of a business decision to discontinue the development
program for MK-8342B for reasons unrelated to safety or efficacy. - | |||
| NCT02668783 2015-004325-14 Details | 2022-02-04 Interventional | 3 | 25 | Estradiol Estradiol 17 be… Estradiol 3-ben… Etonogestrel Ibuprofen Polyestradiol p… Dysmenorrhea Moderate to Sev… | Study terminated by Sponsor as a result of a business decision to discontinue the development
program for MK-8342B for reasons unrelated to safety or efficacy. - | |||
| NCT02616146 2014-002208-26 Details | 2022-02-04 Interventional | 3 | 2016 | Estradiol Estradiol 17 be… Estradiol 3-ben… Ethinyl Estradi… Ethinyl estradi… Etonogestrel Levonorgestrel Polyestradiol p… Contraception | Study terminated by Sponsor as a result of a business decision to discontinue the development
program for MK-8342B for reasons unrelated to safety or efficacy. Because the trial was terminated early, participant diary data used for efficacy analysis and bleeding analysis were not verified. These results should be interpreted with caution. No hypothesis testing was performed. | |||
| NCT00944216 Details | 2022-02-04 Interventional | 4 | 1 | Emollients Abnormalities, … Darier Disease Keratosis Keratosis, Acti… Keratosis Pilar… | terminated due to administrative reasons. - | |||
| NCT00651807 Details | 2022-02-04 Interventional | 2 | 16 | Etonogestrel Hyperplasia Prostatic Hyper… Benign Prostati… | Business Reasons - | |||
| NCT04287179 2019-004234-42 Details | 2022-02-03 Interventional | 3 | 0 | Semaglutide Diabetes Mellit… Diabetes Mellit… | COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In
parallel, the development of a new type of pen injector, which was an important part of the
trial, was ceased and thus this trial was cancelled. - | |||
| NCT01656434 Details | 2022-02-03 Interventional | 3 | 3173 | Ethinyl Estradi… Ferrous fumarat… Contraception | Business reasons - | |||
| NCT00697255 2006-000705-30 Details | 2022-02-03 Interventional | 2 | 8 | Chorionic Gonad… Follicle Stimul… Hormones Infertility Ovulation Induc… | - - | |||
| NCT02236572 Details | 2022-02-01 Interventional | 2 | 17 | Everolimus Breast Neoplasm… Breast Cancer | Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur. - | |||
| NCT05178654 Details | 2022-01-31 Interventional | 1 | 0 | Nirmatrelvir Healthy Partici… | Based on various healthy authorities feedback on PAXLOVID submission, this study is no longer
required. - | |||
| NCT03206463 Details | 2022-01-31 Interventional | 1 | 2 | Dronabinol Bipolar Disorde… Delta-9-Tetrahy… Healthy Control… | Feasibility pilot was completed - | |||
| NCT02335060 Details | 2022-01-31 Interventional | 1 | 5 | Acetylcysteine Dronabinol N-monoacetylcys… Healthy | Feasibility pilot was completed - | |||
| NCT03665129 Details | 2022-01-27 Interventional | 1 | 73 | Avdoralimab Durvalumab Neoplasms Advanced Solid … | early termination - | |||
| NCT00792831 2006-005465-19 Details | 2022-01-27 Interventional | 2 | 3 | Givinostat hydr… Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Protocol needs complete restructuring in order to make it feasible and to complete the
enrollment of 23 patients. - | |||
| NCT00496431 2007-000049-36 Details | 2022-01-27 Interventional | 1/2 | 19 | Givinostat hydr… Histone Deacety… Hodgkin Disease Lymphoma Hodgkin's Lymph… | Study accrual was stopped earlier than planned by the Sponsor for 2 main reasons: very slow
recruitment rate; lower than estimated efficacy of the drug when delivered as single agent. - | |||
| NCT02933944 Details | 2022-01-26 Interventional | 1 | 6 | Pembrolizumab Colorectal Neop… Rectal Cancer | Changing priorities - | |||
| NCT05167370 Details | 2022-01-25 Interventional | 2 | 2 | Amifostine Brain Neoplasms Neoplasms Brain Tumors Solid Tumors | The study was terminated as recommended by the DSMB due to inability to meet enrollment goals
within the time frame allotted (target of 25 patients over 5 years). - | |||
| NCT03447262 2017-004134-29 Details | 2022-01-25 Interventional | 3 | 484 | Ivacaftor VX-659 Cystic Fibrosis Fibrosis | At Sponsor's Discretion - | |||
| NCT04344444 Details | 2022-01-21 Interventional | 3 | 22 | Azithromycin Hydroxychloroqu… COVID-19 | Lack of efficacy data from other studies - | |||
| NCT03207815 2017-001485-17 Details | 2022-01-21 Interventional | 2 | 74 | Prednisone Uveitis Noninfectious U… | Development program terminated Study was terminated early due to termination of the development program. Due to early termination and small sample size, pharmacokinetic (PK) analysis was not performed for this study. |